SESSION TITLE: Safety and Effectiveness of COPD Treatments
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Tuesday, October 25, 2016 at 11:00 AM - 12:15 PM
PURPOSE: The safety of using combination long-acting beta2-agonist and inhaled corticosteroid in COPD patients with co-morbid cardiovascular disease (CVD) has been a concern. The Study to Understand Mortality and MorbidITy in COPD (SUMMIT) provided an opportunity to evaluate the safety of these medicines, alone and in combination, in an extensive number of COPD patients with co-existing CVD and/or risk.